Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis

Curr Opin Nephrol Hypertens. 2002 Nov;11(6):649-55. doi: 10.1097/00041552-200211000-00013.


Serum amyloid P component is a normal plasma protein and a universal non-fibrillar constituent of amyloid deposits. Radiolabelled serum amyloid P component scintigraphy is a non-invasive and quantitative method for imaging amyloid deposits, which produces diagnostic images in most patients with systemic amyloidosis, and can be used repeatedly to monitor the course of the disease. The scintigraphy technique and biopsy histology are complementary, providing a detailed microscopic analysis and a quantitative whole body survey respectively. Clinically useful observations provided by the imaging method include different organ distributions of amyloid in different types of the disease, demonstration of amyloid in anatomic sites not available for biopsy, and evidence for rapid progression and sometimes regression of amyloid deposits with different rates in different organs. Labelled serum amyloid P component studies thus make a unique contribution to the diagnosis and management of individual patients with systemic amyloidosis, and to systematic studies of existing and novel therapies. The technique is available routinely for all known or suspected cases of amyloidosis in the NHS National Amyloidosis Centre at the Royal Free Hospital, but it has not been developed commercially.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Amyloidosis / blood
  • Amyloidosis / diagnostic imaging*
  • Amyloidosis / pathology
  • Humans
  • Radionuclide Imaging
  • Radiopharmaceuticals / pharmacokinetics
  • Serum Amyloid P-Component / analysis*
  • Serum Amyloid P-Component / pharmacokinetics


  • Radiopharmaceuticals
  • Serum Amyloid P-Component